These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11304903)

  • 21. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
    Miller DP; Alfredson T; Cook SF; Sands BE; Walker AM
    Am J Gastroenterol; 2003 May; 98(5):1117-22. PubMed ID: 12809837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
    Sager JE; Lutz JD; Foti RS; Davis C; Kunze KL; Isoherranen N
    Clin Pharmacol Ther; 2014 Jun; 95(6):653-62. PubMed ID: 24569517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
    Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
    Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
    Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
    Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
    Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
    Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
    Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
    Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
    Sagahón-Azúa J; Medellín-Garibay SE; Chávez-Castillo CE; González-Salinas CG; Milán-Segovia RDC; Romano-Moreno S
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00864. PubMed ID: 34523245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
    Gupta SK; Kunka RL; Metz A; Lloyd T; Rudolph G; Perel JM
    J Clin Pharmacol; 1995 Feb; 35(2):202-7. PubMed ID: 7751433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling.
    Jeong HC; Chae YJ; Lee S; Kang W; Yun HY; Shin KH
    J Clin Pharmacol; 2021 Nov; 61(11):1505-1513. PubMed ID: 34118174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
    Koch KM; Corrigan BW; Manzo J; James CD; Scott RJ; Stead AG; Kersey KE
    Aliment Pharmacol Ther; 2004 Jul; 20(2):223-30. PubMed ID: 15233703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
    Simrén M; Simms L; D'Souza D; Abrahamsson H; Björnsson ES
    Aliment Pharmacol Ther; 2003 Jan; 17(2):279-87. PubMed ID: 12534414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of gasoline inhalation on the enantioselective pharmacokinetics of fluoxetine in rats.
    Cardoso JL; Lanchote VL; Pereira MP; Capela JM; Lepera JS
    Chirality; 2013 Mar; 25(3):206-10. PubMed ID: 23362155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of fluoxetine in elderly men and women.
    Ferguson JM; Hill H
    Gerontology; 2006; 52(1):45-50. PubMed ID: 16439824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ischemic colitis during treatment with alosetron.
    Friedel D; Thomas R; Fisher RS
    Gastroenterology; 2001 Feb; 120(2):557-60. PubMed ID: 11159896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.